

Supplementary Figure. The mouse model of haploidentical donor cell infusion.

Supplementary Table. Donor engraftment and GVHD by different doses of donor cell infusion in the mouse model

Donor cells infused (no.)	Chimerism type	GVHD incidence	Death due to GVHD	Median survival
0	Microchimerism (10/10)	0/10	0/10	≥6M
1×10^7	Microchimerism (10/10)	0/10	0/10	≥6M
2×10^7	Microchimerism (10/10)	0/10	0/10	≥6M
4×10^7	Microchimerism (10/10)	0/10	0/10	≥6M
8×10^7	Microchimerism (2/10)	0/2	0/2	≥6M
	FDC (8/10)	0/8	0/8	≥6M

All CB6F1 recipient mice received 200mg/kg cytarabine preconditioning and were assigned to five subgroups based on different infusion numbers of mobilized splenic mononuclear cells from C57BL/6 donor mice: 0, 1×10^7, 2×10^7, 4×10^7, and 8×10^7. There were 10 mice per (sub) group. No GVHD prophylaxis was used in any group. Microchimerism is defined as donor cells $< 1\%$. FDC: full donor chimerism; M: months.